Correlation between immunological abnormalities and prognosis in myelodysplastic syndrome patients

International Journal of Hematology

Volumn 66, Issue 3, 1997, Pages 345-351

  Okamoto, Takahiro ^a   Okada, Masaya ^a   Mori, Ako ^a   Saheki, Kaname ^a   Hiroyuki Takatsuka, ^a   Wada, Hiroshi ^a   Tamura, Amane ^a   Fujimori, Yoshihiro ^a   Yoshinobu Takemoto, ^a   Kanamaru, Akihisa ^a   Kakishita, Eizo ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Immunological abnormalities; Myelodysplastic syndromes; Prognosis

Indexed keywords

ANTINUCLEAR ANTIBODY; CD4 ANTIGEN; CD8 ANTIGEN; DNA ANTIBODY;

ARTICLE; AUTOIMMUNITY; COMPLICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERGAMMAGLOBULINEMIA; INFECTION SENSITIVITY; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE;

EID: 0031257730     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0925-5710(97)00042-x     Document Type: Article

References (21)

1. Hamblin T. Immunologic abnormalities in myelodysplastic syndromes. Hematol Oncol Clin North Am. 6:1992;571-586.
2. Economopoulos T., Ecomonidou J., Giannopoulos G.et al. Immune abnormalities in myelodysplastic syndromes. J Clin Pathol. 38:1985;908-911.
3. Mufti G.J., Figes A., Hamblin T.J., Oscier D.G., Copplestone J.A. Immunological abnormalities in myelodysplastic syndromes. Br J Haematol. 63:1986;143-147.
4. Seitanides B., Antonopoulou A., Karabelis A. Immunological abnormalities in myelodysplastic syndromes. J Clin Pathol. 41:1988;922-923.
5. Baumann M.A., Milson T.J., Patrick C.W., Libnoch J.A., Keller R.H. Immunoregulatory abnormalities in myelodysplastic disorders. Am J Hematol. 22:1986;17-26.
6. Merchav S., Nagler A., Silvian I., Carter A., Tatarsky I., Spira G. Immunoglobulin synthesis in myelodysplastic syndromes: normal B-cell and immunoregulatory T-cell functions. Clin Immuno Immunopathol. 42:1987;195-201.
7. Ayanlar-Batuman O., Shevitz J., Traub U.C., Murphy S., Sajewski D. Lymphocyte interleukin 2 production and responsiveness are altered in patients with primary myelodysplastic syndrome. Blood. 70:1987;494-500.
8. Colombat P.H., Renoux M., Lamagnere J., Renoux G. Immunologic indices in myelodysplastic syndromes. Cancer. 61:1988;1075-1081.
9. Symeonidis A., Kourakli A., Katevas P.et al. Immune function parameters at diagnosis in patients with myelodysplastic syndromes: correlation with the FAB classification and prognosis. Eur J Haematol. 47:1991;277-281.
10. Okabe M., Minagawa T., Nakane A., Sakurada K., Miyazaki T. Impaired α-interferon production and natural killer activity in blood mononuclear cells in myelodysplastic syndromes. Scand J Haematol. 37:1986;111-117.
11. Billstroem R., Johansson H., Johansson B., Mitelman F. Immune-mediated complications in patients with myelodysplastic syndromes - clinical and cytogenetic features. Eur J Haematol. 55:1995;42-48.
12. Enright H., Jacob H.S., Vercellotti G., Howe R., Belzer M., Miller W. Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy. Br J Haematol. 91:1995;403-408.
13. Culligan D.J., Whittaker C.J., Jacobs A., Pauda R.A. Clonal lymphocytes are detectable in only some cases of MDS. Br J Haematol. 81:1992;346-352.
14. Tsukamoto N., Morita K., Maehara T.et al. Clonality in myelodysplastic syndromes: demonstration of pluripotent stem cell origin using X-linked restriction fragment length polymorphisms. Br J Haematol. 83:1993;589-594.
15. Ohyashiki K., Sasao I., Ohyashiki J.H.et al. Cytogenetic and clinical findings of myelodysplastic syndromes with a poor prognosis: an experience of 97 cases. Cancer. 70:1992;94-99.
16. Cunningam I., MacCallum S.J., Nicholls M.D.et al. The myelodysplastic syndromes: an analysis of prognostic factors in 226 cases from a single institution. Br J Haematol. 90:1995;602-606.
17. Morel P., Declercq C., Hebbar M., Bauters F., Fenaux P. Prognostic factors in myelodysplastic syndromes: critical analysis of the impact of age and gender and failure to identify a very low-risk group using standard mortality ratio techniques. Br J Haematol. 94:1996;116-119.
18. Green A.R., Shuttleworth D., Bowen D.T., Bentley D.P. Cutaneous vasculitis in patients with myelodysplasia. Br Haematol. 74:1990;364-370.
19. Reuss-Borst M.A., Pawelec G., Saal J.G., Horny H.P., Mueller C.A., Waller H.D. Sweet's syndrome associtated with myelodysplasia: possible role of cytokines in the pathogenesis of the disease. Br J Haematol. 84:1993;356-358.
20. Pedersen-Bjergaard J., Pedersen M., Roulston D., Philip P. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood. 86:1995;3542-3552.
21. Takashima H., Eguchi K., Origuchi T.et al. Collagen diseases complicated with myelodysplastic syndrome (MDS) - Report of three cases. Rheumati. 34:1994;48-53.